Top

Published in:

02-03-2024 | Pompe Disease | Images in Endocrine Pathology

Primary Multiglandular Parathyroid Disease in the Setting of Pompe Disease

Authors: Meryl Nath, Rumeal D. Whaley, William Sukov, Lori A. Erickson

Published in: Endocrine Pathology | Issue 1/2024

Excerpt

A woman in her 30 s presented with cardiomyopathy and hypercalcemia. She was found to have primary hyperparathyroidism. Imaging revealed 4 gland parathyroid disease. She underwent removal of 3-1/2 parathyroid glands. …

Winkel LPF, Hagemans MLC, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 2005;252:875–84. https://doi.org/10.1007/s00415-005-0922-9.CrossRefPubMed

Hui KS, Williams JC, Borit A, et al. The endocrine glands in Pompe’s disease. Report of two cases. Arch Pathol Lab Med 1985;109:921–5.

Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol 2022;33:64–89. https://doi.org/10.1007/s12022-022-09709-1.CrossRefPubMed

Juhlin CC, Erickson LA. Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice. Endocr Pathol 2021;32:17–34. https://doi.org/10.1007/s12022-020-09656-9.CrossRefPubMed

Erickson LA, Mete O. Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol 2018;29:113–129. https://doi.org/10.1007/s12022-018-9527-6.CrossRefPubMed

Title: Primary Multiglandular Parathyroid Disease in the Setting of Pompe Disease
Authors: Meryl Nath
Rumeal D. Whaley
William Sukov
Lori A. Erickson
Publication date: 02-03-2024
Publisher: Springer US
Keywords: Pompe Disease
Hyperparathyroidism
Parathyroid Disease
Hypercalcemia
Published in: Endocrine Pathology / Issue 1/2024
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-024-09805-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Thyroid gland blastomycosis

Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification

Artificial Intelligence Detected the Relationship Between Nuclear Morphological Features and Molecular Abnormalities of Papillary Thyroid Carcinoma

The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms

The 3rd Edition of Bethesda System for Reporting Thyroid Cytopathology: Highlights and Comments

A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials